Clinical profile of an unselected population with heart failure treated with vericiguat in real life: differences with the VICTORIA trial

IntroductionVericiguat, an oral stimulator of soluble guanylate cyclase, reduces cardiovascular mortality and hospitalisations in patients with heart failure (HF) and reduced ejection fraction, as demonstrated in the VICTORIA trial. This study assessed the real-world use of vericiguat.Material and m...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	Alberto Esteban-Fernández, Alejandro Recio-Mayoral, Raquel López-Vilella, Gregorio de Lara, Moisés Barrantes-Castillo, Inés Gómez-Otero, Julio Nuñez-Villota, Carolina Robles-Gamboa, José López-Aguilera, Ángel Iniesta-Manjavacas, Paula Fluviá, Francisco Pastor-Pérez, Laia Belarte-Tornero, Gonzalo Alonso-Salinas, Pablo Díez-Villanueva
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	Frontiers Media S.A. 2025-01-01
Reeks:	Frontiers in Cardiovascular Medicine
Onderwerpen:	vericiguat worsening heart failure guideline-directed medical therapy VERISEC registry heart failure reduced ejection fraction
Online toegang:	https://www.frontiersin.org/articles/10.3389/fcvm.2024.1504427/full
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!